Latest News and Press Releases

BUDAPEST, Hungary, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announces the first subject dosed in a two-part Phase I trial to evaluate the pharmacokinetics,...

BUDAPEST, Hungary, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings, Ltd (DRGT), Ltd a clinical stage specialty pharmaceutical company, announced the appointment of Lynne Powell...

BUDAPEST, Hungary, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New...

BUDAPEST, Hungary, July 15, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announced the start of a phase 2 randomized, double-blind, placebo-controlled trial to evaluate...

BUDAPEST, Hungary, June 10, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announced results from a pharmacokinetic study of their novel formulation of celecoxib...

NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies USA today announced the expansion of the clinical team, with the addition of Dr. Elizabeth Manning Duus, who has been named...

NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Druggability Technologies USA today announced that Dr.  John E. Friend II has been named as Chief Medical Officer. Druggability Technologies USA has been...

MALTA, May 02, 2018 (GLOBE NEWSWIRE) -- DRGT, a specialty pharmaceutical company with a proprietary formulation technology, announced the results of its successful dose escalation PK study for...

MSIDA, Malta, Oct. 05, 2017 (GLOBE NEWSWIRE) -- DRGT, a specialty pharmaceutical company, today announced the results of its Phase I study of DRGT18-2, a novel formulation of Sirolimus (Rapamune®),...

SWATAR, MALTA--(Marketwired - Dec. 19, 2016) - DRGT, a specialty pharmaceutical company announced today the Phase I clinical results of its DRGT-46 and DRGT-47 programs, new compositions...